Skip to main content
Erschienen in: Journal of Gastroenterology 3/2016

01.03.2016 | Original Article—Liver, Pancreas, and Biliary Tract

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing

verfasst von: Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Satoshi Mochida

Erschienen in: Journal of Gastroenterology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Dual oral therapy with daclatasvir plus asunaprevir yielded an SVR rate of 85 % among patients with genotype 1b HCV. Treatment failure mainly occurred in patients with pre-existing HCV with NS5A-Y93H mutation. The significance of the mutation was evaluated.

Methods

The percent of serum NS5A-Y93H strains relative to the total strains was quantified using cycling-probe real-time PCR combined with direct sequencing in 444 patients with genotype 1b HCV, and the factors associated with mutation were analyzed. The mutation rates during interferon therapy were measured sequentially.

Results

NS5A-Y93H strains (1–100 % of the total strains) were detected in 87 patients (19.6 %). Mutant strains were detected more frequently among women than among men, in patients with a favorable allele in the IL28B-related gene SNP than among those with unfavorable alleles, and among patients without HCC and/or with serum AFP levels less than 6.0 ng/ml than among those with HCC and/or levels of 6.0 ng/ml or more. A multivariate analysis revealed that IL28B-related gene polymorphisms were significant factors associated with mutant strains. Although the frequency of patients with mutant strains was equivalent among patients depending on their previous interferon therapies, a sequential analysis during the interferon administrations revealed that the mutant strains disappeared earlier than the wild-type strains.

Conclusions

NS5A-Y93H mutation was associated with sex, serum AFP levels, and IL28B-related gene polymorphisms in patients infected with genotype 1b HCV. The indications for NS5A inhibitor use should be determined based on these factors, since mutant strains seem to be sensitive to interferon.
Literatur
1.
Zurück zum Zitat Higuch M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002;55:69–77. Higuch M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002;55:69–77.
2.
Zurück zum Zitat Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed
3.
Zurück zum Zitat Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl19):102–7.CrossRefPubMed Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl19):102–7.CrossRefPubMed
4.
Zurück zum Zitat Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174–81.CrossRefPubMed Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174–81.CrossRefPubMed
5.
Zurück zum Zitat Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.CrossRefPubMed Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.CrossRefPubMed
6.
Zurück zum Zitat Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.PubMedCentralCrossRefPubMed Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.CrossRefPubMed Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.CrossRefPubMed
8.
Zurück zum Zitat Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.PubMedCentralCrossRefPubMed Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Sugawara K, Inao M, Nakayama N, et al. Telaprevir-induced, but not PEGylated interferon-associated, retinopathy as a noteworthy. J Gastroenterol. 2014;49:363–8.CrossRefPubMed Sugawara K, Inao M, Nakayama N, et al. Telaprevir-induced, but not PEGylated interferon-associated, retinopathy as a noteworthy. J Gastroenterol. 2014;49:363–8.CrossRefPubMed
10.
Zurück zum Zitat Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:218–27.CrossRef Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:218–27.CrossRef
11.
Zurück zum Zitat Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–53.CrossRefPubMed Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–53.CrossRefPubMed
12.
Zurück zum Zitat Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res. 2015;45:501–13.CrossRefPubMed Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res. 2015;45:501–13.CrossRefPubMed
13.
Zurück zum Zitat Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238–48.PubMedCentralCrossRefPubMed Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238–48.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.CrossRefPubMed Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.CrossRefPubMed
15.
16.
Zurück zum Zitat Sugawara K, Koushima Y, Inao M, et al. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG and RGT Trial. Hepatol Res. 2015;. doi:10.1111/hepr.12475 (In press). Sugawara K, Koushima Y, Inao M, et al. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG and RGT Trial. Hepatol Res. 2015;. doi:10.​1111/​hepr.​12475 (In press).
17.
Zurück zum Zitat Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54.CrossRefPubMed Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54.CrossRefPubMed
18.
Zurück zum Zitat Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.PubMedCentralCrossRefPubMed Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.CrossRefPubMed Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.CrossRefPubMed
20.
Zurück zum Zitat Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Gent. 2009;41:1105–9.CrossRef Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Gent. 2009;41:1105–9.CrossRef
21.
Zurück zum Zitat Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.CrossRefPubMed Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.CrossRefPubMed
22.
Zurück zum Zitat Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variant resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.CrossRefPubMed Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variant resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.CrossRefPubMed
23.
Zurück zum Zitat Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.PubMedCentralCrossRefPubMed Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92–100.CrossRefPubMed Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92–100.CrossRefPubMed
25.
Zurück zum Zitat Asahina Y, Tsuchiya K, Nishimura T, et al. α-fetoprotein levels after interferon therapy and risk of hepatocellular carcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefPubMed Asahina Y, Tsuchiya K, Nishimura T, et al. α-fetoprotein levels after interferon therapy and risk of hepatocellular carcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefPubMed
26.
Zurück zum Zitat Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed
27.
Zurück zum Zitat Akuta N, Suzuki F, Seko Y, et al. Complicated relationship of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;46:2134–41.CrossRef Akuta N, Suzuki F, Seko Y, et al. Complicated relationship of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;46:2134–41.CrossRef
28.
Zurück zum Zitat Abe H, Ochi H, Maekawa T, et al. Common variation of IL28B affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed Abe H, Ochi H, Maekawa T, et al. Common variation of IL28B affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed
29.
Zurück zum Zitat Kobayashi M, Suzuki F, Akuta N, et al. Association of the polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596–605.CrossRefPubMed Kobayashi M, Suzuki F, Akuta N, et al. Association of the polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596–605.CrossRefPubMed
Metadaten
Titel
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing
verfasst von
Yoshihito Uchida
Jun-ichi Kouyama
Kayoko Naiki
Kayoko Sugawara
Satsuki Ando
Masamitsu Nakao
Daisuke Motoya
Mie Inao
Yukinori Imai
Nobuaki Nakayama
Satoshi Mochida
Publikationsdatum
01.03.2016
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 3/2016
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1106-8

Weitere Artikel der Ausgabe 3/2016

Journal of Gastroenterology 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.